ABBV News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

AB

Mkt Cap

$466.45B

Volume

3.19M

Next Earnings

October 30th

Chart Financials Earnings News About Dividends Insider Filings

Wall Street's Bull Case for Bristol Myers Squibb Is Getting LouderBristol Myers Squibb (BMY) is up 17% this year and trades at a discount to peers despite strong Q2 performance with $12.9B revenue and 153% EPS growth. The company's growth portfolio of newer drugs now accounts for nearly 60% of revenue and grew 15% year-over-year, offsetting concerns about patent expirations on legacy drugs. With a 3.95% dividend yield, $5B buyback program, and potential acquisition interest from AstraZeneca, analysts see significant upside potential as the market has underpriced the stock relative to its pipeline execution.The Motley Fool · Sep 20, 2026

Body Contouring Devices Market Expands as Non-Invasive Technology Reaches Untapped Male DemographicThe global body contouring devices market is expected to grow from $2.41 billion in 2025 to $8.82 billion by 2035, with a CAGR of 13.84%. Non-invasive treatments dominate with 78.4% market share, driven by rising obesity rates and increasing demand for non-surgical aesthetic procedures. The U.S. market alone is projected to reach $2.74 billion by 2035. Key growth drivers include expanding male demographics, multi-modal technology platforms, and rising social media influence on aesthetic awareness.GlobeNewswire Inc. · Sep 19, 2026

Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?AstraZeneca's stock has declined following several late-stage pipeline failures including Wainua in ATTR-CM, Ultomiris in HSCT-TMA, volrustomig in NSCLC, and Etcamah in breast cancer. However, the company maintains a broad pipeline with over 20 expected high-value readouts in the next 18 months, particularly in oncology. The stock trades at a reasonable valuation of 16.29x forward earnings, below industry average, though 2026-2027 earnings estimates have been revised downward.Zacks Investment Research · Sep 18, 2026

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?AbbVie and Bristol Myers Squibb are compared as pharmaceutical investment options for 2026. AbbVie is recommended as the better buy due to its successful immunology franchise with Skyrizi and Rinvoq driving growth, diversification into aesthetics and neuroscience, and having navigated its patent cliff challenges. Bristol Myers Squibb, while cheaper on valuation metrics and maintaining strong profit margins, faces revenue stagnation, legal uncertainties from a Celgene acquisition lawsuit, and is still working through its own portfolio transition challenges.The Motley Fool · Sep 18, 2026

Autoimmune Disease Therapeutics Market Set for Growth Through 2034 as Biologics, Precision Medicine and Pipeline Innovation Reshape the Competitive LandscapeThe global autoimmune disease therapeutics market is projected to grow from USD 132.75 billion in 2025 to USD 254.60 billion by 2034, at a CAGR of 7.5%. Growth is driven by rising autoimmune disease diagnoses, increased adoption of biologics and targeted oral therapies, biosimilar expansion, and emerging cell and gene therapies. Biologics dominate with 66% market share, TNF inhibitors lead drug classes at 29%, and rheumatoid arthritis accounts for 34% of revenue. North America holds 44% regional share while Asia-Pacific is expected to grow fastest.GlobeNewswire Inc. · Sep 17, 2026

Billionaire Ken Griffin Just Loaded Up on This Dividend King, and Wall Street Still Sees UpsideKen Griffin's Citadel hedge fund increased its AbbVie stake by over 500% in Q2 2026, signaling confidence in the pharmaceutical company's defensive qualities and dividend strength. AbbVie, a Dividend King with 50+ consecutive annual dividend increases, offers a 2.6% yield and has successfully navigated patent cliffs with new drugs like Skyrizi and Rinvoq. Wall Street analysts remain bullish with 25 of 31 rating it a buy and an average price target of $277.The Motley Fool · Sep 15, 2026

AbbVie (ABBV) Advances While Market Declines: Some Information for InvestorsAbbVie stock rose 1.78% to $261.70, outperforming a declining S&P 500. The company has gained 3.07% over the past month, exceeding sector losses. Analysts expect strong earnings growth of 107.53% YoY with revenue projected at $17.36 billion (+10.02% YoY). AbbVie holds a Zacks Rank #3 (Hold) with a Forward P/E of 18.3, trading at a premium to its industry average.Zacks Investment Research · Sep 14, 2026

AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?The article compares AbbVie, a mature pharmaceutical company with stable cash flows and a growing immunology portfolio, against CRISPR Therapeutics, a clinical-stage biotech firm pioneering gene-editing therapies. AbbVie is recommended as the better choice for 2026 due to its profitability, strong free cash flow generation, and rising dividend, while CRISPR offers high-reward potential but faces significant cash burn and execution risks.The Motley Fool · Sep 14, 2026

Parexel to Lead Sessions at DPHARM 2026 on AI, Talent and the Future of Clinical OperationsParexel announced it will lead three expert panel sessions at DPHARM 2026 in Boston on enterprise AI adoption, workforce readiness, and patient-centric drug development. The company showcased its proprietary ParexelAI suite, which has delivered significant efficiency gains including 50% reduction in site selection timelines, 30% reduction in clinical study report preparation time, and 60% reduction in safety literature screening. CEO Peyton Howell and other executives will moderate discussions with leaders from major pharmaceutical companies including AbbVie, AstraZeneca, Boehringer Ingelheim, Regeneron, and Merck.GlobeNewswire Inc. · Sep 14, 2026

State Street XLV vs. iShares IXJ: Here's How These Healthcare ETFs Stack Up for InvestorsXLV and IXJ are two healthcare ETFs with different approaches: XLV focuses on 60 U.S. S&P 500 healthcare stocks with a low 0.08% expense ratio and stronger recent returns, while IXJ offers broader global diversification with 110 holdings across multiple countries but charges a higher 0.38% expense ratio. The choice depends on whether investors prioritize cost efficiency and domestic concentration or international diversification.The Motley Fool · Sep 13, 2026

AB

ABBVABBVIE INC.

ABBV

Pay with—

Available Balance0.00

Your PositionYou don't own any ABBV yet.

Related Tickers

Earnings

Dividends

Ex Oct 15

Amount$1.73

PaysNov 16

Last · Jul 15Quarterly

Amount$1.73

Yield2.62%

Annual$6.92